Company Announcement
- Major shareholder announcement for Genmab A/S
COPENHAGEN, Denmark, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to
Section 29 of the Danish Securities Trading Act that FIL Investment Management Limited has informed us that, as of September 9,
2016, FMR LLC (Fidelity Management and Research) has decreased their indirect ownership in Genmab A/S to 2,975,738 shares, which
amounts to 4.94% of the share capital and voting rights in Genmab A/S.
About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated
antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra(r)
(ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX(r) (daratumumab) for the treatment
of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma
indications and for non-Hodgkin's lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody technologies - the DuoBody(r) platform for
generation of bispecific antibodies, and the HexaBody(r) platform which creates effector function enhanced antibodies. The
company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has
alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and
"plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any
future results or performance expressed or implied by such statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products,
uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to
product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment
in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes
and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks,
please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or
revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless
required by law.
Genmab A/S and its subsidiaries own the following trademarks: Genmab(r); the Y-shaped Genmab logo(r);
Genmab in combination with the Y-shaped Genmab logo(tm); the DuoBody logo(r); the HexaBody logo(tm);
HuMax(r); HuMax-CD20(r); DuoBody(r); HexaBody(r) and UniBody(r).
Arzerra(r) is a trademark of Novartis AG or its affiliates. DARZALEX(r) is a trademark of Janssen Biotech,
Inc.
Company Announcement no. 42
CVR no. 2102 3884
Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark
